Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results

Higher product sales were accompanied by lower GAAP earnings and increased research and commercial expenses.

Rhea-AI Summary

Neurocrine Biosciences (NBIX) reported third-quarter 2026 revenue of $1.1 billion, up 41% year over year, and raised its INGREZZA sales outlook. INGREZZA sales rose 17% to $801 million, CRENESSITY sales increased 115% to $211 million, and VYKAT XR contributed $107 million. GAAP net income declined to $206.5 million from $209.5 million; diluted earnings fell to $1.96 from $2.04.

The company raised expected 2026 INGREZZA sales to $2.9–$2.925 billion from $2.825–$2.875 billion and lowered its selling, general and administrative expense outlook. Cash, cash equivalents and marketable securities totaled approximately $790 million, versus $2.543 billion at year-end 2025. Neurocrine initiated a Phase 1 obesity study and a Phase 2 study for cognitive impairment in Alzheimer's disease. It expects Phase 3 readouts for osavampator in depression and direclidine in schizophrenia in 2027.

13 points · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 12 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point. Forward-looking: it has not happened yet and may not happen.2026 INGREZZA sales guidance raised to $2.9–$2.925 billion from $2.825–$2.875 billion.
• Moderate pointThird-quarter revenue grew 41% year over year to $1.1 billion.
• Moderate point. Forward-looking: it has not happened yet and may not happen.2026 GAAP SG&A guidance lowered to $1.540–$1.560 billion from $1.575–$1.600 billion.
• Moderate pointThird-quarter operating income increased to $331.3 million from $239.0 million a year earlier.
• Minor pointINGREZZA sales increased 17% year over year to $801 million in third-quarter 2026.

8 minor points

• Minor pointCRENESSITY sales increased 115% year over year to $211 million in third-quarter 2026.
• Minor pointVYKAT XR sales contributed $107 million in third-quarter 2026.
• Minor pointNine-month revenue increased to $2,896.2 million from $2,055.0 million in 2025.
• Minor pointNine-month GAAP net income rose to $548.8 million from $324.9 million; diluted EPS increased to $5.26 from $3.19.
• Minor pointNBIP-'1968 Phase 1 study initiated to evaluate safety and tolerability in obesity development.
• Minor pointNBI-'567 Phase 2 study initiated for adjunctive treatment of cognitive impairment in Alzheimer's disease.
• Minor pointKINECT-PRO Phase 4 open-label results showed sustained patient-reported quality-of-life and functionality improvements with INGREZZA.
• Minor point. Forward-looking: it has not happened yet and may not happen.2027 Phase 3 readouts expected for osavampator in major depressive disorder and direclidine in schizophrenia.

Negative

• Moderate pointThird-quarter GAAP net income fell to $206.5 million from $209.5 million; diluted EPS declined to $1.96 from $2.04.
• Moderate pointCash, cash equivalents and marketable securities fell to approximately $790 million from $2.543 billion at year-end 2025.
• Moderate pointThird-quarter GAAP R&D expense rose to $351.8 million from $250.0 million a year earlier.
• Moderate pointThird-quarter GAAP SG&A expense increased to $366.3 million from $291.6 million a year earlier.
• Minor pointThird-quarter cost of revenues, excluding acquired-intangible amortization, rose to $26.6 million from $13.0 million.

7 minor points

• Minor pointThird-quarter acquired-intangible amortization increased to $35.0 million from $1.0 million a year earlier.
• Minor pointThird-quarter acquired in-process R&D expense increased to $11.7 million from $0.3 million a year earlier.
• Minor pointEquity investments generated a $52.3 million unrealized loss versus a $30.6 million gain in third-quarter 2025.
• Minor pointThird-quarter investment income and other, net, declined to $5.0 million from $22.2 million a year earlier.
• Minor point. Forward-looking: it has not happened yet and may not happen.2026 acquired in-process R&D expense guidance increased to $34 million from $23 million.
• Minor point. Forward-looking: it has not happened yet and may not happen.2026 GAAP R&D guidance remains $1.275–$1.325 billion, including approximately $33 million in development milestone expenses.
• Minor point. Forward-looking: it has not happened yet and may not happen.2026 acquired-intangible amortization guidance remains $85–$90 million.

Argus 15 min delay 7 alerts

+6.68% vs previous close $155.06 last price 1.7x rel. volume Open Argus

Details

Market move: NBIX +6.68% vs previous close. Third-quarter 2026 earnings report

$142.50 – $160.85 Day Range

$15.76B Mkt Cap at Last Price

On Nov 2, the day this news came out, the latest delayed price for NBIX is 6.68% above the previous close. Our momentum scanner has recorded 7 alerts for this stock so far that day. The latest delayed price is $155.06. Relative volume is above average at 1.7x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Total revenue: $1,122.7 million INGREZZA net product sales: $801 million CRENESSITY net product sales: $211 million +4 more

Total revenue

$1,122.7 million

Q3 2026; +41% year-over-year from $794.9 million

INGREZZA net product sales

$801 million

Q3 2026; +17% year-over-year

CRENESSITY net product sales

$211 million

Q3 2026; +115% year-over-year

VYKAT XR net product sales

$107 million

Q3 2026

INGREZZA 2026 sales guidance

$2.9–$2.925 billion

Raised from $2.825–$2.875 billion

GAAP net income

$206.5 million

Q3 2026; compared with $209.5 million in Q3 2025

Non-GAAP net income

$346.7 million

Q3 2026; compared with $222.1 million in Q3 2025

Previous Earnings Reports

1 past event · Latest: Jul 30

Same Type 1 event

1. Jul 30

   Q2 2026 earnings

   24h Move

   -10.1%

   Raised 2026 INGREZZA sales guidance to $2.825–$2.875 billion after revenue growth.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pharmacokinetics, tardive dyskinesia, open-label, gaap

4 terms

pharmacokinetics medical

"evaluating the efficacy, safety, tolerability and pharmacokinetics of NBI-'567"

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

tardive dyskinesia medical

"improvements in clinician-rated tardive dyskinesia (TD) movement severity"

A chronic movement disorder marked by repetitive, involuntary motions—often of the face, tongue, or limbs—that can develop after long-term use of certain psychiatric or neurological medications. It matters to investors because the condition creates medical need, regulatory scrutiny, potential for expensive treatments or liability, and can shape the commercial value of drugs in development or on the market; think of it as a persistent side effect that can change a drug’s price tag and sales prospects.

open-label medical

"Phase 4 open-label study results demonstrating that treatment"

Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.

gaap financial

"Third-quarter 2026 GAAP net income and earnings per share"

GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Total Third-Quarter 2026 Revenue Grew 41% Year-Over-Year to $1.1 Billion

INGREZZA^® (valbenazine) 2026 Net Sales Guidance Raised to $2.9 to $2.925 Billion

SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2026.

"Our third quarter performance marks another important milestone in Neurocrine's evolution, with net product sales exceeding $1 billion for the first time, driven by strong underlying demand across our diversified portfolio of first-in-class medicines," said Kyle W. Gano, Ph.D., Chief Executive Officer of Neurocrine Biosciences. "This continued growth reinforces the strength of our strategy and expands our capacity to invest in innovation, advance our pipeline and build an enduring biopharmaceutical company. Looking ahead to 2027, we see meaningful opportunities for continued growth across INGREZZA, CRENESSITY^® (crinecerfont) and VYKAT^® (diazoxide choline) XR, alongside multiple important clinical milestones, including Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia."

Total Revenue Highlights

	Three Months Ended September 30,
(unaudited, in millions, except per share data)	2026		2025		YoY Growth
Revenues:
INGREZZA Net Product Sales	$           801		$           687		17 %
CRENESSITY Net Product Sales	211		98		115 %
VYKAT XR Net Product Sales	107		—		NM
Other Revenues	4		10		NM
Total Revenues	$        1,123		$           795		41 %

• Total revenues for the third-quarter 2026 were $1.1 billion, compared with $795 million in the prior-year period representing 41% year-over-year growth.
• INGREZZA third-quarter 2026 net product sales were $801 million, representing 17% growth year-over-year. Results reflected double-digit volume growth, with record TRx and NRx supported by strong demand and high rates of persistency.
• INGREZZA full year 2026 guidance was increased from a range of $2.825 billion to $2.875 billion up to $2.9 billion to $2.925 billion.
• CRENESSITY third-quarter 2026 net product sales were $211 million, driven by steady new patient demand and high rates of persistency with approximately 80% reimbursement for dispensed prescriptions.
• VYKAT XR third-quarter 2026 net product sales were $107 million, driven by steady and consistent patient demand and persistency.

Recent Clinical and Corporate Developments

• Announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-'1968, an investigational GLP-1/GIP/glucagon receptor triple agonist being developed as a therapy for obesity. This follows the Q1 2026 initiation of a Phase 1 first-in-human clinical study of NBIP-'2118, a potential first-in-class CRF2 peptide agonist. Initial clinical data from both programs will inform the development of a novel co-formulated combination therapy, including the optimal ratio of the two agents. NBIP-'2118 will also be evaluated independently as a potential standalone therapy for obesity.
• Announced the initiation of a Phase 2 clinical study evaluating the efficacy, safety, tolerability and pharmacokinetics of NBI-'567, an investigational M1/M4 (M1-preferring) selective muscarinic agonist being developed as an adjunctive therapy for cognitive impairment in Alzheimer's disease.
• Announced publication of the KINECT-PRO™ Phase 4 open-label study results demonstrating that treatment with once-daily INGREZZA capsules resulted in substantial and sustained improvements in patient-reported quality of life and functionality, alongside improvements in clinician-rated tardive dyskinesia (TD) movement severity. Improvements were observed regardless of underlying psychiatric diagnosis or baseline TD movement severity, including among participants with clinician-rated mild TD movements. The manuscript appears in CNS Spectrums.
• Presented research advancing the understanding of Prader-Willi syndrome and real-world experience with VYKAT XR at the Foundation for Prader-Willi Research Symposium & Family Conference.
• Announced that Eiry W. Roberts, M.D., who previously served as Neurocrine's Chief Medical Officer and most recently as a Strategic Advisor, has rejoined the Company's executive management team as Chief Medical Officer (CMO).
• Company to host R&D Day in New York on December 15, 2026.

 

Third-Quarter 2026 Financial Results

	Three Months Ended September 30,
(unaudited, in millions, except per share data)	2026		2025
Total Revenues	$          1,123		$             795
GAAP Cost of Revenues	$               27		$               13
Non-GAAP Cost of Revenues	$               20		$               13
GAAP Research and Development (R&D)	$             352		$             250
Non-GAAP R&D	$             317		$             228
GAAP Selling, General, and Administrative (SG&A)	$             366		$             292
Non-GAAP SG&A	$             327		$             259
GAAP Net Income	$             207		$             210
GAAP Earnings Per Share – Diluted	$            1.96		$            2.04
Non-GAAP Net Income	$             347		$             222
Non-GAAP Earnings Per Share – Diluted	$            3.29		$            2.17
(unaudited, in millions)	September 30, 2026		December 31, 2025
Total Cash, Cash Equivalents, and Marketable Securities	$             790		$          2,543

• Third-quarter 2026 GAAP net income and earnings per share were $207 million and $1.96, respectively, compared with $210 million and $2.04, respectively, for third-quarter 2025.
• Third-quarter 2026 Non-GAAP net income and earnings per share were $347 million and $3.29, respectively, compared with $222 million and $2.17, respectively, for third-quarter 2025.
• A reconciliation of GAAP to Non-GAAP financial results can be found in Table 3 at the end of this press release.
• Third-quarter 2026 GAAP and Non-GAAP net income compared with third-quarter 2025 were primarily driven by:
  • Higher net product sales of $329 million.
  • Third-quarter 2026 GAAP operating expenses included certain expenses associated with the acquisition of Soleno Therapeutics, Inc. (Soleno), which closed in May 2026, and are excluded from Non-GAAP operating expenses.
  • Increased R&D expense in support of an expanded and advancing pre-clinical and clinical portfolio included investments in the osavampator Phase 3 program in major depressive disorder (MDD) and the muscarinic franchise, including the direclidine Phase 3 program as a potential treatment for adults with schizophrenia. Development milestone expense included in R&D was $10 million and $1 million, respectively, for the third quarter 2026 and 2025.
  • Increased SG&A expense primarily reflected continued investment in our commercial organization, included the expansion of our INGREZZA and CRENESSITY sales teams in the first quarter of 2026 and for support of VYKAT XR following the acquisition of Soleno, which closed in May 2026.
  • Third-quarter 2026 includes $52 million loss from changes in fair values of equity investments, compared with a gain of $31 million for third quarter 2025 (Non-GAAP adjustment)
• At September 30, 2026, the Company had cash, cash equivalents, and marketable securities totaling approximately $790 million.

Full Year 2026 Financial Guidance

(dollars in millions)	Prior		Updated
INGREZZA Net Product Sales 1	$2,825 - $2,875		$2,900 - $2,925
GAAP R&D 2	$1,275 - $1,325		No Change
Non-GAAP R&D 2, 3	$1,140 - $1,190		No Change
IPR&D 4	$23		$34
GAAP SG&A 5	$1,575 - $1,600		$1,540 - $1,560
Non-GAAP SG&A 3, 5	$1,325 - $1,350		$1,290 - $1,310
GAAP Amortization of Acquired Intangible Assets 6	$85 - $90		No Change

1. INGREZZA sales guidance reflects expected net product sales of INGREZZA in tardive dyskinesia and chorea associated with Huntington's disease.
2. R&D guidance reflects the continued advancement of the Company's pre-clinical and clinical portfolio including the Phase 3 programs for osavampator in major depressive disorder and direclidine in schizophrenia, and includes approximately $33 million of expense for development milestones related to our in-licensed product candidates. Development milestones are included in R&D guidance once achieved or deemed probable to achieve.
3. Non-GAAP guidance has been adjusted to exclude estimated non-cash stock-based compensation expense of approximately $115 million in R&D and $170 million in SG&A, including approximately $58 million related to the acceleration of vesting of equity awards for Soleno employees which vested in full upon the closing of the transaction, and acquisition, integration and divestiture-related expenses of approximately $95 million. Non-cash stock-based compensation expense for performance-based equity awards is included in guidance once the predefined performance-based criteria for vesting is achieved or deemed probable to achieve.
4. IPR&D guidance represents completed collaboration and licensing arrangements.
5. SG&A guidance reflects expense for ongoing commercial initiatives, including the recent expansion of our sales teams in Q1 2026, supporting INGREZZA growth and the launch of CRENESSITY and VYKAT XR.
6. In connection with the acquisition of Soleno, the Company recorded approximately $2.2 billion of intellectual property related to VYKAT XR to the balance sheet, which will be amortized over an expected life of 16 years.

Conference Call and Webcast Today at 4:30 PM Eastern Time
Neurocrine Biosciences will hold a live conference call and webcast today at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Participants can access the live conference call by dialing 800-347-6865 (US) or 203-518-9757 (International) using the conference ID: NBIX. The webcast and accompanying slides can also be accessed at approximately 4:30 p.m. Eastern Time on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, YOU DESERVE BRAVE SCIENCE, INGREZZA, and CRENESSITY are registered trademarks of Neurocrine Biosciences, Inc. VYKAT is a registered trademark of Soleno Therapeutics, Inc.

Non-GAAP Financial Measures
In addition to the financial results and financial guidance that are provided in accordance with accounting principles generally accepted in the United States (GAAP), this press release also contains the following Non-GAAP financial measures: Non-GAAP cost of revenues, Non-GAAP R&D expense, Non-GAAP SG&A expense, Non-GAAP other income (expense), net, Non-GAAP net income and earnings per share. When preparing the Non-GAAP financial results and guidance, the Company excludes certain GAAP items that management does not consider to be normal, including recurring cash operating expenses that might not meet the definition of unusual or non-recurring items. In particular, these Non-GAAP financial measures exclude: non-cash stock-based compensation expense, amortization expense related to acquired intangible assets, amortization expense related to acquisition-date inventory fair value step-up, stock based compensation expense related to the acceleration of vesting of equity awards for Soleno employees, changes in fair value of equity investments, acquisition-related transaction and integration costs, gains on sales of businesses, net of transaction costs, other divestiture-related transaction costs, changes in foreign currency exchange rates and certain adjustments to income tax expense. These Non-GAAP financial measures are provided as a complement to results provided in accordance with GAAP as management believes these Non-GAAP financial measures are useful to investors because they help indicate underlying trends in the Company's business, are important in comparing current results with prior period results and provide additional information regarding the Company's financial position. Management also uses these Non-GAAP financial measures to establish budgets and operational goals that are communicated internally and externally and to manage the Company's business and evaluate its performance. The Company provides guidance regarding combined R&D and SG&A expenses on both a GAAP and a Non-GAAP basis. A reconciliation of these GAAP financial results to Non-GAAP financial results is included in the attached financial information.

Forward-Looking Statements
In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: our business strategy, objectives, and future development plans; the benefits to be derived from our products and product candidates; the value our products and/or our product candidates may bring to patients; the continued success of INGREZZA; successfully commercializing CRENESSITY and VYKAT XR; our financial and operating performance, including our future revenues, expenses, or profits; our full year 2026 financial guidance; our acquisition of Soleno Therapeutics, including the prospective benefits of the acquisition, and our strategy, plans, objectives, expectations (financial or otherwise) and intentions with respect to our future financial results, growth potential and anticipated product portfolio in connection with the acquisition; our collaborative partnerships; clinical and scientific data updates for our products and product candidates, including observations regarding clinical outcomes, safety, and tolerability; expected future clinical and regulatory milestones; and the timing of the initiation and/or completion of our clinical, regulatory, and other development activities and those of our collaboration partners. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements, include but are not limited to the following: risks and uncertainties associated with Neurocrine Biosciences' business and finances in general; risks and uncertainties associated with the commercialization of our products; risks related to our ability to realize the anticipated benefits of the acquisition of Soleno Therapeutics, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period and that we will not be able to integrate Soleno Therapeutics' business successfully or that such integration may be more difficult, time-consuming or costly than expected, disruption from the acquisition, making it more difficult to conduct business as usual or maintain relationships with employees, customers, suppliers, other business partners or governmental entities, unknown or inestimable liabilities, the risk of litigation and/or regulatory actions related to the acquisition, and the degree and pace of market uptake of VYKAT XR; risks related to the development of our product candidates; risks associated with our dependence on third parties for development, manufacturing, and commercialization activities for our products and product candidates, and our ability to manage these third parties; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates; risks that development activities may not be initiated or completed on time or at all, or may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that the potential benefits of the agreements with our collaboration partners may never be realized; risks that our products, and/or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks associated with government and third-party regulatory and/or policy efforts which may, among other things, impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products; risks associated with competition from other therapies or products, including potential generic entrants for our products; risks associated with our ability to manage the growth of our organization; and other risks described in our periodic reports filed with the Securities and Exchange Commission. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than as required by law.

###

TABLE 1
NEUROCRINE BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(unaudited, in millions, except per share data)
	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
Revenues:
Net product sales	$      1,119.0		$         789.9		$      2,884.3		$      2,035.6
Collaboration revenues	3.7		5.0		11.9		19.4
Total revenues	1,122.7		794.9		2,896.2		2,055.0
Operating expenses:
Cost of revenues, excluding amortization of acquired intangible assets	26.6		13.0		63.5		31.5
Research and development	351.8		250.0		974.7		757.5
Acquired in-process research and development	11.7		0.3		34.4		0.4
Selling, general, and administrative	366.3		291.6		1,124.5		854.4
Amortization of acquired intangible assets	35.0		1.0		51.5		3.0
Gain on sale of business, net of transaction costs	—		—		(28.6)		—
Total operating expenses	791.4		555.9		2,220.0		1,646.8
Operating income	331.3		239.0		676.2		408.2
Other (expense) income :
Interest expense	(0.3)		—		(3.2)		—
Unrealized (loss) gain on equity investments	(52.3)		30.6		(25.8)		(6.7)
Investment income and other, net	5.0		22.2		45.5		64.5
Total other (expense) income, net	(47.6)		52.8		16.5		57.8
Income before provision for income taxes	283.7		291.8		692.7		466.0
Provision for income taxes	77.2		82.3		143.9		141.1
Net income	$         206.5		$         209.5		$         548.8		$         324.9
Earnings per share, basic	$           2.03		$           2.11		$           5.43		$           3.27
Earnings per share, diluted	$           1.96		$           2.04		$           5.26		$           3.19
Weighted average common shares outstanding, basic	101.6		99.4		101.0		99.3
Weighted average common shares outstanding, diluted	105.2		102.5		104.3		102.0

 

TABLE 2
NEUROCRINE BIOSCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in millions)
	September 30, 2026		December 31, 2025
Cash, cash equivalents, and marketable securities	$              737.9		$          1,480.4
Accounts receivable	957.3		686.8
Inventory	66.1		69.0
Other current assets	246.9		286.5
Total current assets	2,008.2		2,522.7
Noncurrent inventory	177.7		—
Noncurrent marketable securities	51.8		1,063.0
Right-of-use assets	437.2		455.4
Equity investments	95.0		120.8
Property and equipment, net	92.2		89.8
Intangible assets, net	2,191.0		4.7
Goodwill	500.6		6.1
Deferred tax assets	11.8		320.3
Other noncurrent assets	61.9		48.7
Total assets	$          5,627.4		$          4,631.5
Total current liabilities	984.6		743.4
Deferred tax liabilities	105.0		—
Noncurrent operating lease liabilities	392.3		415.3
Other noncurrent liabilities	266.8		219.7
Stockholders' equity	3,878.7		3,253.1
Total liabilities and stockholders' equity	$          5,627.4		$          4,631.5

 

TABLE 3
NEUROCRINE BIOSCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS
(unaudited, in millions, except per share data)
	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
GAAP net income 1	$       206.5		$       209.5		$       548.8		$       324.9
Adjustments:
Stock-based compensation expense	54.3		53.7		176.5		159.3
Acceleration of stock-based compensation expense and related taxes 2	—		—		60.1		—
Acquisition-related employee compensation and severance costs	16.7		—		38.6		—
Amortization of inventory fair value step-up 3	6.3		—		9.3		—
Amortization of acquired intangible assets 4	35.0		1.0		51.5		3.0
Acquisition/divestiture-related transaction and integration costs	1.9		—		50.6		—
Gain on sale of business, net of transaction costs 5	—		—		(28.6)		—
Changes in fair values of equity investments 6	52.3		(30.6)		25.8		6.7
Other 7	1.9		0.8		3.2		3.1
Income tax effect related to reconciling items 8	(28.2)		(12.3)		(91.9)		(37.1)
Non-GAAP net income 1	$       346.7		$       222.1		$       843.9		$       459.9
Diluted earnings per share:
GAAP	$         1.96		$         2.04		$         5.26		$         3.19
Non-GAAP	$         3.29		$         2.17		$         8.09		$         4.51
	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
Cost of Revenues:
GAAP cost of revenues	$              26.6		$              13.0		$              63.5		$              31.5
Adjustments:
Acceleration of stock-based compensation expense and related taxes 2	—		—		1.8		—
Acquisition-related employee compensation and severance costs	—		—		0.2		—
Amortization of inventory fair value step-up 3	6.3		—		9.3		—
Non-GAAP cost of revenues	$              20.3		$              13.0		$              52.2		$              31.5
Research and Development:
GAAP R&D	$            351.8		$            250.0		$            974.7		$            757.5
Adjustments:
Stock-based compensation expense	24.7		22.0		76.4		66.6
Acceleration of stock-based compensation expense and related taxes 2	—		—		18.1		—
Acquisition-related employee compensation and severance costs	8.9		—		13.9		—
Other 7	1.2		—		1.2		—
Non-GAAP R&D	$            317.0		$            228.0		$            865.1		$            690.9
Selling, General, and Administrative:
GAAP SG&A	$            366.3		$            291.6		$         1,124.5		$            854.4
Adjustments:
Stock-based compensation expense	29.6		31.7		100.1		92.7
Acceleration of stock-based compensation expense and related taxes 2	—		—		40.2		—
Acquisition-related employee compensation and severance costs	7.8		—		24.5		—
Acquisition/divestiture-related transaction and integration costs	1.9		—		45.5		—
Other 7	0.4		0.5		1.5		2.4
Non-GAAP SG&A	$            326.6		$            259.4		$            912.7		$            759.3
Amortization of Acquired Intangible Assets:
GAAP amortization of acquired intangible assets	$              35.0		$                1.0		$              51.5		$                3.0
Adjustments:
Amortization of acquired intangible assets 4	35.0		1.0		51.5		3.0
Non-GAAP amortization of acquired intangible assets	$                 —		$                 —		$                 —		$                 —
Gain on Sale of Business, Net of Transaction Costs:
GAAP gain on sale of business, net of transaction costs	$                 —		$                 —		$            (28.6)		$                 —
Adjustments:
Gain on sale of business, net of transaction costs 5	—		—		(28.6)		—
Non-GAAP gain on sale of business, net of transaction costs	$                 —		$                 —		$                 —		$                 —
Other Income (Expense):
GAAP other (expense) income, net	$            (47.6)		$              52.8		$              16.5		$              57.8
Adjustments:
Changes in fair values of equity investments 6	52.3		(30.6)		25.8		6.7
Acquisition/divestiture-related transaction and integration costs	—		—		5.1		—
Other 7	0.3		0.3		0.5		0.7
Non-GAAP other income, net	$                5.0		$              22.5		$              47.9		$              65.2

1.	Includes the following expenses:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
Milestones (R&D)	$             10.0		$               1.0		$             32.9		$             61.5
Acquired in-process research and development (IPR&D)	$             11.7		$               0.3		$             34.4		$               0.4

2.	Relates to the acceleration of vesting of equity awards for Soleno employees which vested in full upon the closing of the transaction.
3.	Relates to amortization expense associated with recording approximately $168 million of VYKAT XR inventory fair value step-up.
4.	Primarily relates to amortization of acquired intangible assets associated with the recording of approximately $2.2 billion of intellectual property related to VYKAT XR, which will be amortized over 16 years.
5.	Reflects a pre-tax gain, net of transaction costs, recognized on the sale of Neurocrine Group Limited in January 2026.
6.	Reflects periodic fluctuations in the fair values of equity investments.
7.	Reflects non-cash interest expense related to the Company's credit facility, legacy campus facility costs, net of sublease income, and other immaterial costs that management does not consider indicative of the Company's ongoing operating performance.
8.	Estimated income tax effect of Non-GAAP reconciling items are calculated using applicable statutory tax rates, taking into consideration any valuation allowance. In addition, Non-GAAP tax expense may also be affected by certain non-recurring, non-operating, or discrete tax items.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-reports-third-quarter-2026-financial-results-302926995.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How did Neurocrine Biosciences perform in the third quarter of 2026?

Neurocrine reported 41% year-over-year revenue growth to $1.1 billion, while GAAP net income declined to $206.5 million from $209.5 million. Diluted earnings per share were $1.96, compared with $2.04 a year earlier.

What is Neurocrine's updated 2026 INGREZZA sales guidance?

Neurocrine expects $2.9–$2.925 billion in 2026 INGREZZA net product sales, up from $2.825–$2.875 billion. The outlook covers treatment of tardive dyskinesia and chorea associated with Huntington's disease.

How does Neurocrine plan to develop its obesity drug combination?

Neurocrine plans to use initial clinical data from NBIP-'1968 and NBIP-'2118 to inform development of a co-formulated combination, including the optimal ratio of the agents. NBIP-'2118 will also be evaluated independently as a potential standalone obesity therapy.

What did Neurocrine's KINECT-PRO study show for INGREZZA?

The Phase 4 open-label study found sustained improvements in patient-reported quality of life and functionality, alongside improvements in clinician-rated tardive dyskinesia movement severity. Improvements were observed regardless of underlying psychiatric diagnosis or baseline movement severity, including among participants with clinician-rated mild movements.

How is Neurocrine accounting for VYKAT XR intellectual property acquired with Soleno?

Neurocrine recorded approximately $2.2 billion of VYKAT XR intellectual property on its balance sheet following the Soleno acquisition, which closed in May 2026. That intellectual property will be amortized over an expected life of 16 years.